In Vivo2022 turned out to be a relatively quiet year on the M&A and partnering front in Japan – or at least it was until mid-December, when Takeda Pharmaceutical Co. Ltd. announced it would pay an eye-wate
Scrip2022 turned out to be a relatively quiet year on the M&A and partnering front in Japan – or at least it was until mid-December, when Takeda Pharmaceutical Co. Ltd. announced it would pay an eye-wate
ScripHigh-profile mRNA specialist Moderna, Inc. has put some of its financial windfall from the COVID-19 pandemic to use by entering into a definitive agreement to acquire OriCiro Genomics , a Japanese